☰

Alexey A. Lugovskoy, Ph.D. - Publications

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
structural aspects of protein function
Tree Info Similar researchers PubMed Report error

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Camblin AJ, Tan G, Curley MD, Yannatos I, Iadevaia S, Rimkunas V, Mino-Kenudson M, Bloom T, Schoeberl B, Drummond DC, Lugovskoy AA, Louis CU, Askoxylakis V. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports. 9: 16832. PMID 31728045 DOI: 10.1038/S41598-019-53322-Y  0.314
2019 Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, ... ... Lugovskoy AA, et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering. 3: 264-280. PMID 30952988 DOI: 10.1038/S41551-019-0385-4  0.306
2019 Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, ... ... Lugovskoy AA, et al. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America. PMID 30898885 DOI: 10.1073/Pnas.1819085116  0.404
2016 Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. Mabs. 0. PMID 27854147 DOI: 10.1080/19420862.2016.1259047  0.366
2016 Ko AH, Murray J, Horgan KE, Dauer J, Curley M, Baum J, Louis CU, Lugovskoy A. A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 34: TPS481-TPS481. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps481  0.315
2016 Kamoun WS, Oyama S, Kornaga T, Feng T, Luus L, Pham MT, Kirpotin DB, Marks JD, Geddie M, Xu L, Lugovskoy AA, Murphy M, Morrisson C, Drummond DC. Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation: Cancer Research. 76: 750-750. DOI: 10.1158/1538-7445.Am2016-750  0.33
2016 Curley MD, Tan G, Yannatos I, Camblin A, Iadevaia S, Louis C, Lugovskoy A. Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models Cancer Research. 76: 1209-1209. DOI: 10.1158/1538-7445.Am2016-1209  0.35
2015 Kohli N, Jain N, Geddie ML, Razlog M, Xu L, Lugovskoy AA. A novel screening method to assess developability of antibody-like molecules. Mabs. 7: 752-8. PMID 25961854 DOI: 10.1080/19420862.2015.1048410  0.365
2015 Zhang K, Geddie ML, Kohli N, Kornaga T, Kirpotin DB, Jiao Y, Rennard R, Drummond DC, Nielsen UB, Xu L, Lugovskoy AA. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. Mabs. 7: 42-52. PMID 25484041 DOI: 10.4161/19420862.2014.985933  0.382
2015 Pace E, Adams S, Camblin A, Curley M, Rimkunas V, Nie L, Iadevaia S, Tan G, Baum J, Czibere AG, Lugovskoy A. Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology. 33: 289-289. DOI: 10.1200/Jco.2015.33.3_Suppl.289  0.345
2015 Curley M, Czibere A, Lugovskoy A. Abstract POSTER-THER-1411: MM-141, an IGF-1R and ErbB3 directed tetravalent bispecific antibody, inhibits ovarian cancer cell growthin vitro Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1411  0.349
2015 Lugovskoy AA, Curley M, Baum J, Adams S, Iadevaia S, Rimkunas V, Camblin A, Nie L, Tan G, Johnson B, Mathews S, Horgan K, Louis CU, Czibere AG, Arnedos M, et al. Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct237  0.33
2015 Adams S, Curley MD, Camblin AJ, Iadevaia S, Nie L, Tan G, Louis CU, Lugovskoy AA. Abstract A89: Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A89  0.356
2014 Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ. 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland. Mabs. 6: 309-26. PMID 24492298 DOI: 10.4161/Mabs.27903  0.337
2014 Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ, Schoeberl B, ... ... Lugovskoy AA, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics. 13: 410-25. PMID 24282274 DOI: 10.1158/1535-7163.Mct-13-0255  0.342
2014 Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods (San Diego, Calif.). 65: 95-104. PMID 23872324 DOI: 10.1016/J.Ymeth.2013.07.017  0.364
2014 Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, van Vlijmen HW, Pepinsky RB, Simon KJ, Lugovskoy A. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework. Methods (San Diego, Calif.). 65: 68-76. PMID 23816785 DOI: 10.1016/J.Ymeth.2013.06.024  0.346
2013 Marcotte D, Zeng W, Hus JC, McKenzie A, Hession C, Jin P, Bergeron C, Lugovskoy A, Enyedy I, Cuervo H, Wang D, Atmanene C, Roecklin D, Vecchi M, Vivat V, et al. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorganic & Medicinal Chemistry. 21: 4011-9. PMID 23647822 DOI: 10.1016/J.Bmc.2013.04.019  0.346
2013 Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, Kontermann RE, Mabry R. 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. Mabs. 5: 339-57. PMID 23493119 DOI: 10.4161/Mabs.24105  0.334
2013 Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy AA. Rapid optimization and prototyping for therapeutic antibody-like molecules. Mabs. 5: 237-54. PMID 23392215 DOI: 10.4161/Mabs.23363  0.384
2013 Euw EMV, Pace E, Covarrubias K, Jairam A, Chai D, Konkankit V, Gong K, Johnson B, Schoeberl B, Lugovskoy A, Richard F, Slamon D. Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-2077A  0.361
2013 Adams S, Baum J, Sparta B, Rimkunas V, Tang J, Pace E, Rosenthal S, Camblin A, Iadevaia S, Czibere A, Nielsen U, Lugovskoy A. Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C169  0.319
2012 Lugovskoy AA, Reichert JM, Beck A. 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. Mabs. 4: 134-52. PMID 22453093 DOI: 10.4161/Mabs.4.2.19426  0.331
2012 Johnson B, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A, Adams S, Baum J, Tang J, Iadevaia S, Kohli N, Rennard R, Sundararajan P, Xu L. Abstract A38: MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A38  0.373
2012 Baum J, Johnson B, Adams S, Tang J, Kohli N, Rennard R, Sundararajan P, Xu L, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A. Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity Cancer Research. 72: 2719-2719. DOI: 10.1158/1538-7445.Am2012-2719  0.353
2011 Fitzgerald J, Lugovskoy AA. Rational engineering of antibody therapeutics targeting multiple oncogene pathways Mabs. 3: 299-309. PMID 21393992 DOI: 10.4161/Mabs.3.3.15299  0.373
2011 Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, Joseph I, Boccia A, Kelly R, Wortham K, Wang Q, ... ... Lugovskoy A, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. The Journal of Biological Chemistry. 286: 4703-17. PMID 21123183 DOI: 10.1074/Jbc.M110.184317  0.39
2011 Lugovskoy A, Johnson B, Baum J, Adams S, Tang J, Kohli N, Rennard R, Xu L, Jiao Y, Nilesen U, Fitzgerald J. Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B205  0.362
2010 Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, Long K, Brazell T, Durugkar KA, Maki J, Ramana CV, Schaffhausen B, Wagner G, Torchilin V, Yuan J, Degterev A. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proceedings of the National Academy of Sciences of the United States of America. 107: 20126-31. PMID 21041639 DOI: 10.1073/Pnas.1004522107  0.49
2010 di Clemente N, Jamin SP, Lugovskoy A, Carmillo P, Ehrenfels C, Picard JY, Whitty A, Josso N, Pepinsky RB, Cate RL. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Molecular Endocrinology (Baltimore, Md.). 24: 2193-206. PMID 20861221 DOI: 10.1210/Me.2010-0273  0.367
2010 Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Current Opinion in Chemical Biology. 14: 520-528. PMID 20638324 DOI: 10.1016/J.Cbpa.2010.06.175  0.376
2010 Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Engineering, Design & Selection : Peds. 23: 549-57. PMID 20457695 DOI: 10.1093/Protein/Gzq028  0.356
2010 Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis Protein Science. 19: 954-966. PMID 20198683 DOI: 10.1002/Pro.372  0.368
2010 Caravella JA, Wang D, Glaser SM, Lugovskoy A. Structure-Guided Design of Antibodies Current Computer - Aided Drug Design. 6: 128-138. DOI: 10.2174/157340910791202469  0.343
2009 Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. Mabs. 1: 128-41. PMID 20061822 DOI: 10.4161/Mabs.1.2.7631  0.379
2009 Yin S, Proctor EA, Lugovskoy AA, Dokholyan NV. Fast screening of protein surfaces using geometric invariant fingerprints. Proceedings of the National Academy of Sciences of the United States of America. 106: 16622-6. PMID 19805347 DOI: 10.1073/Pnas.0906146106  0.311
2009 Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, Fernandez EJ, Wang D, Lugovskoy A. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins. 77: 832-41. PMID 19626705 DOI: 10.1002/Prot.22502  0.389
2009 Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ, Demarest SJ. Conserved amino acid networks involved in antibody variable domain interactions. Proteins. 76: 99-114. PMID 19089973 DOI: 10.1002/Prot.22319  0.305
2008 Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, Cuervo H, Berkowitz S, Zheng T, Guckian K, Pellegrini M, Lugovskoy A. Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure (London, England : 1993). 16: 798-808. PMID 18462684 DOI: 10.1016/J.Str.2008.02.012  0.36
2008 Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick SM, Gerber SA, Lugovskoy A, Yuan J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nature Chemical Biology. 4: 313-21. PMID 18408713 DOI: 10.1038/Nchembio.83  0.467
2007 Zhong W, Dixit SB, Mallis RJ, Arthanari H, Lugovskoy AA, Beveridge DL, Wagner G, Reinherz EL. CTL recognition of a protective immunodominant influenza A virus nucleoprotein epitope utilizes a highly restricted Vbeta but diverse Valpha repertoire: functional and structural implications. Journal of Molecular Biology. 372: 535-48. PMID 17658550 DOI: 10.1016/J.Jmb.2007.06.057  0.434
2006 Clark LA, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, Hanf KJ, Jarpe M, Liparoto SF, Li Y, Lugovskoy A, Miller S, Rushe M, Sherman W, Simon K, Van Vlijmen H. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Science : a Publication of the Protein Society. 15: 949-60. PMID 16597831 DOI: 10.1110/Ps.052030506  0.373
2006 Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, Ingold K, Tardivel A, Krushinskie D, Eldredge J, Silvian L, Lugovskoy A, Farrington GK, Strauch K, Schneider P, Whitty A. Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry. 45: 2006-13. PMID 16475789 DOI: 10.1021/Bi051685O  0.321
2003 Gross JD, Moerke NJ, von der Haar T, Lugovskoy AA, Sachs AB, McCarthy JE, Wagner G. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell. 115: 739-50. PMID 14675538 DOI: 10.1016/S0092-8674(03)00975-9  0.66
2003 Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR, Brugge JS, et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell. 114: 99-111. PMID 12859901 DOI: 10.1016/S0092-8674(03)00480-X  0.478
2002 Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D, Dobles M, Hertig S, Hofmann K, Van Vlijmen H, Hsu YM, Burkly LC, Tschopp J, Zheng TS. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The Journal of Biological Chemistry. 278: 5444-54. PMID 12466268 DOI: 10.1074/Jbc.M210783200  0.34
2002 Lugovskoy AA, Degterev AI, Fahmy AF, Zhou P, Gross JD, Yuan J, Wagner G. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. Journal of the American Chemical Society. 124: 1234-40. PMID 11841292 DOI: 10.1021/Ja011239Y  0.651
2002 Müller J, Lugovskoy AA, Wagner G, Lippard SJ. NMR structure of the [2Fe-2S] ferredoxin domain from soluble methane monooxygenase reductase and interaction with its hydroxylase. Biochemistry. 41: 42-51. PMID 11772001 DOI: 10.1021/Bi015668K  0.592
2001 Zhou P, Lugovskoy AA, Wagner G. A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins. Journal of Biomolecular Nmr. 20: 11-4. PMID 11430750 DOI: 10.1023/A:1011258906244  0.491
2001 Zhou P, Lugovskoy AA, McCarty JS, Li P, Wagner G. Solution structure of DFF40 and DFF45 N-terminal domain complex and mutual chaperone activity of DFF40 and DFF45. Proceedings of the National Academy of Sciences of the United States of America. 98: 6051-5. PMID 11371636 DOI: 10.1073/Pnas.111145098  0.515
2001 Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL Nature Cell Biology. 3: 173-182. PMID 11175750 DOI: 10.1038/35055085  0.488
1999 Lugovskoy AA, Zhou P, Chou JJ, McCarty JS, Li P, Wagner G. Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis. Cell. 99: 747-55. PMID 10619428 DOI: 10.1016/S0092-8674(00)81672-4  0.607
Show low-probability matches.